AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 4.8

Change

0.00 (0.00)%

Market Cap

USD 1.28B

Volume

2.45M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.13B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 111.91B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 37.99B
ARGX argenx NV ADR

N/A

USD 33.78B
BGNE BeiGene Ltd

N/A

USD 26.57B
MRNA Moderna Inc

N/A

USD 21.07B
RPRX Royalty Pharma Plc

N/A

USD 16.63B
UTHR United Therapeutics Corporatio..

N/A

USD 16.00B
SMMT Summit Therapeutics PLC

N/A

USD 14.66B
PCVX Vaxcyte Inc

N/A

USD 14.16B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
ITB 4.19 % 0.42 %

N/A

N/A
RFG Invesco S&P MidCap 400® .. 2.17 % 0.35 %

N/A

N/A
AFMC First Trust Active Factor.. 1.53 % 0.00 %

N/A

USD 0.01B
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
EZM WisdomTree U.S. MidCap Ea.. 1.21 % 0.38 %

N/A

N/A
WDSC:LSE SPDR MSCI World Small Cap.. 0.21 % 0.00 %

N/A

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.21 % 0.00 %

N/A

N/A
ZPRS:F SSgA SPDR ETFs Europe II .. 0.21 % 0.00 %

N/A

USD 0.83B
IUSN:F iShares MSCI World Small .. 0.20 % 0.00 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
ONEO SPDR® Russell 1000 Momen.. 0.00 % 0.20 %

N/A

N/A
VAMO 0.00 % 0.64 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.47% 26% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.47% 26% F 26% F
Trailing 12 Months  
Capital Gain 87.50% 54% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.50% 54% F 76% C+
Trailing 5 Years  
Capital Gain -62.73% 24% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.73% 24% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -0.21% 50% F 40% F
Dividend Return -0.21% 50% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.38% 45% F 24% F
Risk Adjusted Return -0.27% 50% F 36% F
Market Capitalization 1.28B 82% B 74% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector